Latigo Biotherapeutics
Update in progressLTGO (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Latigo Biotherapeutics, Inc. develops non-opioid pain medicines that aim to stop pain transmission without addiction risk. Its pipeline centers on NaV1.8 inhibitors: LTG-001, an oral agent for fast-acting, opioid-sparing relief in acute pain; LTG-321, for chronic musculoskeletal pain starting with osteoarthritis; and LTG-418 for both acute and chronic pain. Formerly WVB-Desmond, it renamed Latigo in March 2019. Established in 2018, based in Thousand Oaks, California.
Company score
- Sentiment
- 0.41
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.17
- Governance
- 0.08
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.07
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.24
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!